心房纤颤并发冠状动脉疾病患者的抗栓治疗研究进展
被引量：1
摘要
约1／3的心房纤颤患者同时患有冠状动脉疾病^[1]。临床医师常遇见的难题是对有高危卒中风险（CHADS：评分≥2）需给予口服抗凝药物而同时有冠状动脉疾病又需给予抗血小板药物甚至双联抗血小板药物的心房纤颤患者如何治疗的问题，
出处
《医学研究杂志》
2013年第5期20-22,共3页
Journal of Medical Research
二级参考文献31
-
1Ho PM,Maddox TM,Wang L,Fihn SD,Jesse RL,Peterson ED,Rumsfeld JS.Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. The Journal of The American Medical Association . 2009 被引量：2
-
2O‘Donoghue ML,Braunwald E,Antman EM,Murphy SA,Bates ER,Rozenman Y,Michelson AD,Hautvast RW,Ver Lee PN,Close SL,Shen L,Mega JL,Sabatine MS,Wiviott SD.Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhib-itor: an analysis of two randomised trials. The Lancet . 2009 被引量：2
-
3Dewilde W,Berg JT.Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST). American Heart Journal . 2009 被引量：2
-
4The ACTIVE Writing Group on behalf of the ACTIVE Investigators.Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet,The . 2006 被引量：2
-
5Karjalainen PP,Vikman S,Niemel M,Porela P,Ylitalo A,Vaittinen MA,Puurunen M,Airaksinen TJ,Nyman K,Vahlberg T,Airaksinen KE.Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. European Heart Journal . 2008 被引量：2
-
6Sarafoff N,Ndrepepa G,Mehilli J, et al.Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. Journal of Internal Medicine . 2008 被引量：2
-
7Ruiz-Nodar JM,Marín F,Sánchez-Payá J,Hurtado JA,Valencia-Martín J,Manzano-Fernández S,Roldán V,PérezAndreu V,Sogorb F,Valdés M,Lip GY.Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. European Heart Journal . 2009 被引量：2
-
8Hlg C,Brunner-La Rocca HP,Kaiser C,Jeger R,Osswald S,Pfisterer M,Hoffmann A.Early and late increased bleeding rates after angioplasty and stenting due to combined antiplatelet and anticoagulanttherapy. EuroIntervention . 2009 被引量：1
-
9Rubboli A,Colletta M,Sangiorgio P,Di Pasquale G.Antithrombotic treatment after coronary artery stenting in patients on chronic oral anticoagulation: an international survey of current clinical practice. Italian Heart Journal . 2004 被引量：1
-
10Rubboli A,Schlitt A,Airaksinen J,Lip GY.Bleeding after coronary stenting in patients on oral anticoagulation: who is guilty. EuroIntervention . 2010 被引量：1
共引文献3
-
1李为民,韩薇.2010年急性冠脉综合征抗栓治疗进展[J].中国医学前沿杂志（电子版）,2011,3(1):31-34. 被引量：3
-
2赵梦华,石建平,陈海鱼.口服抗凝药物置入冠状动脉支架患者的抗栓治疗策略[J].医学综述,2013,19(13):2373-2375. 被引量：3
-
3李晓静,陈晓敏.血小板P2Y12受体基因多态性与氯吡格雷抵抗相关性研究[J].浙江大学学报（医学版）,2014,43(3):333-338. 被引量：8
-
1吴楠,顾晴,关玉霞,李宾宾.心房颤动患者华法林抗凝治疗的管理现状[J].中华护理杂志,2014,49(3):337-340. 被引量：46
-
2刘英明,杨晔,李田昌.口服抗凝药物预防心房颤动患者脑卒中的研究进展[J].中国心血管杂志,2012,17(3):231-233. 被引量：7
-
3张学义,潘维恩,王乃震,牛晓棠.CHA2DS2-VASc评分系统在房颤患者健康管理中的应用[J].中国卫生产业,2013,10(6):82-82.
-
4姚璐,张薇,田国祥,夏常泉,武云涛,王晓兵,李娟.达比加群酯应用于高龄老年非瓣膜性心房纤颤患者中的安全性评价[J].中国循证心血管医学杂志,2016,8(5):547-549. 被引量：16
-
5赵明磊,毕齐.心房颤动合并急性冠状动脉综合征患者的抗栓治疗研究进展[J].心肺血管病杂志,2016,35(12):992-995. 被引量：1
-
6万槐斌,杨艳敏.新型口服抗凝药物与急性冠状动脉综合征的二级预防[J].中华心血管病杂志,2015,43(5):455-458. 被引量：3
-
7Yusu.,S,许俊堂.冠状动脉疾病的口服抗凝药物治疗：汇总分析[J].美国医学会杂志（中文版）,2000,19(6):304-312.
-
8江梅.急性心肌梗死患者常用口服抗凝药物的效果分析[J].检验医学与临床,2007,4(9):908-908.
-
9李丹,李亚刚,等.肝硬化、门脉高压症行脾切除术后早期应用抗凝药物的意义[J].吉林医学,2002,23(4):219-220. 被引量：6
-
10石建平,赵梦华,徐宝元.置入冠状动脉支架房颤患者的三联抗栓治疗[J].中国循证心血管医学杂志,2012,4(6):582-583. 被引量：1
